Last reviewed · How we verify
NCT06760520
Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer
Phase 2 trial testing Ivonescimab (SMT112 or AK112) Injection in Locally Advanced Rectal Cancer in 40 participants. Not yet recruiting.
20 December 2027
Quick facts
| Lead sponsor | The First Affiliated Hospital of Zhengzhou University |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 20 January 2025 |
| Primary completion | 20 December 2027 |
| Estimated completion | 20 December 2031 |
Drugs / interventions tested
- Ivonescimab (SMT112 or AK112) Injection — full drug profile →
Conditions studied
- Locally Advanced Rectal Cancer — all drugs for Locally Advanced Rectal Cancer →
Sponsor
The First Affiliated Hospital of Zhengzhou University
Who can join
Adults 18 to 75, any sex, with Locally Advanced Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single-arm, prospective, phase II clinical study to evaluate the efficacy and safety of preoperative short-course radiotherapy combined with ivonescimab and chemotherapy + total mesorectal excision(TME) surgery in patients with advanced rectal cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06760520
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ivonescimab (SMT112 or AK112) Injection
Trials testing the same drug.
- NCT06913218 — A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically R · Phase 1 · not yet recruiting
Other recruiting trials for Locally Advanced Rectal Cancer
Currently open trials in the same condition.
- NCT07527026 — A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant T · Phase 2 · recruiting
- NCT07514754 — Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients · NA · recruiting
- NCT07150949 — Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MS · Phase 2 · recruiting
- NCT07057089 — Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I) · Phase 2 · recruiting
- NCT06894797 — Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer. · NA · recruiting
Other The First Affiliated Hospital of Zhengzhou University trials
Trials by the same sponsor.
- NCT07501962 — Effect of Intraluminal Administration of Menthol Solution During Colonoscopy on Colonic Spasm and Adenoma Detection Rate · NA · not yet recruiting
- NCT07501975 — Effect of a Novel Colonoscopic Lavage Solution on Colonoscopy Quality · NA · not yet recruiting
- NCT07454954 — The Effect of Blood Flow Restriction Training Combined With Transcranial Magnetic Stimulation on Limb Function in Hemipl · NA · not yet recruiting
- NCT05114941 — Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome · NA · not yet recruiting
- NCT07314619 — Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combi · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06760520 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Zhengzhou University
- Last refreshed: 8 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06760520.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing